Glasgow, Scotland May 19, 2022 (Issuewire.com) – PharmacyOnline.co.uk pharmacists conducted open data research that shows that 28% of adults are obese while 36.2% of adults are overweight based on their BMI but are not categorically obese.
Weight management is key in shedding the pounds, but there are a lot of genetic and other physiological and external factors for those who are already obese or in need of losing weight.
Wegovy is a revolutionary new prescription weight-loss medicine that has been shown to help patients take off and keep off pounds.
This injectable prescription medicine can be prescribed for patients who are overweight (excess weight) and have a body mass index (BMI) of 30 or higher. Wegovy is a prescription medicine (semaglutide) and is prescribed to be injected once a week in order to supplement the process of weight loss.
This medication is specifically for adults who are imploring chronic weight management and who are within the ranges of obese and overweight. For those who are overweight, Wegovy is prescribed as long as there is weight-related comorbidity like hypertension or type 2 diabetes.
Additionally, Wegovy should be used alongside a calorie-deficient diet and regular physical activity. What the medication does in aid of weight loss is suppress one’s appetite, lower one’s calorie intake, and regulate one’s appetite for better results.
Wegovy mimics the action of GLP-1 produced naturally by the gut and to a lesser extent the pancreas and nervous system. GLP-1 targets the brain’s appetite control mechanisms, making you feel fuller for longer. It also slows how quickly your stomach empties, which helps to keep you feeling fuller for even longer.
Wegovy is manufactured by Novo Nordisk, a Pharmaceutical company founded in 1923. Their goal is to fight the rampant increase of patients with diabetes and other illnesses and comorbidities related to it such as obesity and other endocrine diseases.
0141 952 5918
32 Welbeck Road, Glasgow, Scotland. G53 7SD
This article was originally published by IssueWire. Read the original article here.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Prestige Standard journalist was involved in the writing and production of this article.